Clinical Benefits of ABX464 for Ulcerative Colitis Revealed in Review Study

Clinical Benefits of ABX464 for Ulcerative Colitis Revealed in Review Study
Abivax has published a review study summarizing the mechanisms, as well as the previously undisclosed clinical benefits of ABX464, its treatment candidate for people with inflammatory diseases, including ulcerative colitis (UC). ABX464, undergoing clinical testing for several inflammatory diseases, will soon be evaluated in a Phase 2/3 trial for Crohn’s disease, the company announced. The review, “Specific and selective induction of miR-124 in immune cells by the quinoline ABX464: a transformative therapy for inflammatory diseases,” was published in the journal Drug Discovery Today. “Our recent publication in Drug Discovery Today once again demonstrates the unique mechanism of action and transformative potential of our lead drug candidate ABX464 to effectively and durably treat chronic inflammatory diseases,” Hartmut J. Ehrlich, MD, CEO of Abivax, said in a press release. Over the past decades, scientists have investigated the role of microRNAs as key players in regulating immune responses. MicroRNAs are tiny RNA molecules that regulate gene activity within cells. They bind to a gene’s messenger RNA (mRNA) — the molecule generated from DNA and used as the template for protein production — to prevent the generation of that protein. Depending on their target mRNA, microRNAs might either promote or suppress inflammation, making them attractive targets for potential therapies. The levels of a particular microRNA called miR-124, which has the ability to dampen inflammation, were previously found to be reduced in patients with certain autoimmune diseases. Importantly, increasing levels of miR-124 were found to inhibit intestinal inflammation by suppressing the activity of a main regulator of the inflammatory response, called STAT3. ABX464, an
Subscribe or to access all post and page content.